Unleashing meaningful innovation through regulatory reform
EPHA #A2MDialogues
19 October 2020
17:00-18:00
online
The first in a series of online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.
Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe.
What effect do the shortcomings of current assessment processes have on the quality of innovation?
How do we resolve the conundrum of high prices and high uncertainty?
Our panelists discussed how regulatory and payment systems could be adapted to incentivise the timely generation of quality comparative data on the benefits and harms of new drugs and high-risk devices both before and after their market entry, profiting patients, clinicians, and healthcare systems.
Panelists
Beate Wieseler,
Head, Drug Assessment Department,
Institute for Quality and Efficiency in Health Care (IQWiG)
Huseyin Naci
Assistant Professor of Health Policy
London School of Economics and Political Science
Lydie Meheus PhD
Managing Director
Belgian Anticancer Fund
Andrea Cipriani MD PhD
Professor of Psychiatry
University of Oxford
Moderated by
Yannis Natsis
Policy Manager, Universal Access and Affordable Medicines
European Public Health Alliance
On social media
#A2MDialogues Interesting question today: "What do we know when we approve medicines? Do we know enough?" @EPHA_EU
— Marie Guichardon (@mguichardon) October 19, 2020
Interesting deliberations on the use of real-world data and how to get outcomes that matter for the patients, clinicians and healthcare systems @EPHA_EU @IQWiG @HuseyinNaci2 @And_Cipriani @lydie_meheus @Anticancerfund https://t.co/PmgofY30by
— RWE4Decisions (@RWE4Decisions) October 19, 2020
“Companies need to standardise their approach to #clinicaltrials, we have the tools, methods in place.” Says @Huseyinaci2 #a2mdialogues @EPHA_EU pic.twitter.com/PZ9oefptAL
— Neha Dave (@NehaDave) October 19, 2020
📉Better evidence, particularly from comparative RCTs, needed to enable confident decision-making in HTA and P&R! @iqwig @Anticancerfund @EPHA_EU #A2MDialogues
— Anna Prokůpková (@AnnaProEU) October 19, 2020
💊Check out @CancerLeagues priorities for #EUPharmaStrategy: 🔗https://t.co/Dcc9E9bIBv https://t.co/WUWTRt4DPx
🔬Companies are pursuing similar #research without sharing data. @EMA_News should encourage those developers to collaborate when providing scientific advice and include asking for HTA and payer relevant criteria! @EPHA_EU #A2MDialogues
— Anna Prokůpková (@AnnaProEU) October 19, 2020
🔗https://t.co/Dcc9E9bIBv pic.twitter.com/WXND65RqhW
Very grateful I could participate to EPHA's first #A2MDialogues with Beate Wieseler @IQWiG, @HuseyinNaci2 and @And_Cipriani. I hope the regulator will take the HTA needs for comparative evidence into its Scientific Advice on short notice.#anticancerfund #cancerresearch@EPHA_EU pic.twitter.com/AYURbrm867
— Lydie Meheus (@lydie_meheus) October 19, 2020
Find out more about the other #A2MDialogues in the series below
The EU's IP strategy: Enabler or barrier?
27 October 2020
17:00-18:00
Pharma & COVID19: Winners, losers, prospects
19 November 2020
16:00-17:00
The Presidencies’ perspective on the pharmaceutical strategy: Europe’s to-do list on access to medicines
25 November 2020
16:00-17:30
